Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Hepatic steatosis associated with exposure to elvitegravir and raltegravir

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Kirkegaard-Klitbo, Ditte Marie ; Thomsen, Magda Teresa ; Gelpi, Marco ; Bendtsen, Flemming ; Nielsen, Susanne Dam ; Benfield, Thomas. / Hepatic steatosis associated with exposure to elvitegravir and raltegravir. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 ; Vol. 73, No. 3. pp. e811-e814.

Bibtex

@article{37c09967be6e47f2920e0086586e1c4f,
title = "Hepatic steatosis associated with exposure to elvitegravir and raltegravir",
abstract = "Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.",
keywords = "HIV Infections/complications, Humans, Prospective Studies, Quinolones/adverse effects, Raltegravir Potassium/adverse effects, NAFLD, ART, HIV",
author = "Kirkegaard-Klitbo, {Ditte Marie} and Thomsen, {Magda Teresa} and Marco Gelpi and Flemming Bendtsen and Nielsen, {Susanne Dam} and Thomas Benfield",
note = "{\textcopyright} Crown copyright 2021.",
year = "2021",
month = aug,
doi = "10.1093/cid/ciab057",
language = "English",
volume = "73",
pages = "e811--e814",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "University of Chicago Press",
number = "3",

}

RIS

TY - JOUR

T1 - Hepatic steatosis associated with exposure to elvitegravir and raltegravir

AU - Kirkegaard-Klitbo, Ditte Marie

AU - Thomsen, Magda Teresa

AU - Gelpi, Marco

AU - Bendtsen, Flemming

AU - Nielsen, Susanne Dam

AU - Benfield, Thomas

N1 - © Crown copyright 2021.

PY - 2021/8

Y1 - 2021/8

N2 - Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.

AB - Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.

KW - HIV Infections/complications

KW - Humans

KW - Prospective Studies

KW - Quinolones/adverse effects

KW - Raltegravir Potassium/adverse effects

KW - NAFLD

KW - ART

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=85113710760&partnerID=8YFLogxK

U2 - 10.1093/cid/ciab057

DO - 10.1093/cid/ciab057

M3 - Journal article

C2 - 33493297

VL - 73

SP - e811-e814

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -

ID: 61877758